Shares of Arbutus Biopharma Corp. (NASDAQ:ABUS) saw an uptick in trading volume on Tuesday . 146,061 shares traded hands during trading, an increase of 34% from the previous session’s volume of 108,732 shares.The stock last traded at $3.80 and had previously closed at $3.94.

Several brokerages recently weighed in on ABUS. Zacks Investment Research lowered shares of Arbutus Biopharma Corp. from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. Wedbush reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Arbutus Biopharma Corp. in a research report on Friday, April 22nd. Leerink Swann reiterated a “buy” rating and set a $12.00 price target on shares of Arbutus Biopharma Corp. in a report on Thursday, May 5th. Finally, Chardan Capital started coverage on Arbutus Biopharma Corp. in a report on Monday, May 16th. They set a “sell” rating and a $3.25 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Arbutus Biopharma Corp. presently has an average rating of “Hold” and a consensus price target of $9.79.

The company’s market cap is $199.38 million. The stock has a 50 day moving average of $3.94 and a 200 day moving average of $3.94.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.36. Analysts expect that Arbutus Biopharma Corp. will post ($1.41) EPS for the current year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.